Biotech | February 17, 2022
Pebble engages MD Anderson to evaluate multi-cannabinoid formulations in ovarian cancer
Despite advances over the past 20 years, ovarian cancer treatment requires better standard of care
Despite advances over the past 20 years, ovarian cancer treatment requires better standard of care
Collaboration aims to evolve precision medicine with cell-specific delivery of gene therapy
Dr. Peter Houghton will lead the research collaboration for GCCRI and is widely regarded as a leading expert in pediatric cancer research and in the development of novel approaches to treating childhood cancers
BDR Pharmaceuticals is a home-grown company with operations in India and overseas. It’s known for its formulations portfolio and has a presence in specialty medicines. The company has ambitious plans as it has ramped up capacity and looking to foray into regulated markets. Raheel Shah, Director, BDR Group of Companies shares his insights in an interview with Thomas C Thottathil, Editor, Indian Pharma Post
Senior R&D leader from Pfizer and bluebird bio to support Strand’s platform of programmable mRNA-based therapeutics
In the first phase of the Grangemouth site expansion, two new ADC manufacturing suites, operational by Q3 2023, will be added to the existing three
Fiscal support in line with what is available in key innovation hubs such as USA and China will drive the next leg of drug discovery in India
Market data indicates that more than twenty percent of the new chemical entities being developed use roller compaction technology in their development and commercialization
The new collaboration focuses on a class of proteins called transcription factors, which control gene expression and can regulate important cellular processes including cell growth and survival
The stability is led by healthy demand in the domestic and emerging markets
Subscribe To Our Newsletter & Stay Updated
